JNJ-26481585
- Product Name
- JNJ-26481585
- CAS No.
- 875320-29-9
- Chemical Name
- JNJ-26481585
- Synonyms
- CS-1098;Quisinostat;JNJ-26481585;Quisinostat HClbase;JNJ26481585;JNJ 26481585;Quisinostat (JNJ-26481585);Quisinostat (JNJ-26481585) 2HCl;JNJ-26481585 JNJ26481585 Quisinostat;N1-(2-(1H-indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diaMine;N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-car
- CBNumber
- CB42500942
- Molecular Formula
- C21H26N6O2
- Formula Weight
- 394.47
- MOL File
- 875320-29-9.mol
JNJ-26481585 Property
- Density
- 1.35
- storage temp.
- Store at -20°C
- solubility
- insoluble in H2O; insoluble in EtOH; ≥19.2 mg/mL in DMSO
- form
- Powder
N-Bromosuccinimide Price
- Product number
- 14088
- Product name
- JNJ-26481585
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $71
- Updated
- 2022/04/27
- Product number
- 14088
- Product name
- JNJ-26481585
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $177
- Updated
- 2022/04/27
- Product number
- 14088
- Product name
- JNJ-26481585
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $317
- Updated
- 2022/04/27
- Product number
- 14088
- Product name
- JNJ-26481585
- Purity
- ≥98%
- Packaging
- 50mg
- Price
- $703
- Updated
- 2022/04/27
- Product number
- J211333
- Product name
- JNJ-26481585
- Packaging
- 5mg
- Price
- $275
- Updated
- 2021/12/16
JNJ-26481585 Chemical Properties,Usage,Production
Uses
JNJ-26481585 is an HDAC1, HDAC2, HDAC4, HDAC10, and HDAC11 inhibitor. Potent Histone deacetylase inhibitor.
Definition
ChEBI: N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide is a member of indoles.
Biological Activity
jnj-26481585 is a novel histone deacetylase (hdac) inhibitor that exerts a strong potency towards class i hdac (including hdac1, hdac2 and hdac3), with values of inhibition constant ic50 of 0.11, 0.33 and 4.8 nmol/l respectively, leading to strong anti-proliferative activities (ic50 ranging from 3.1 to 246 nmol/l) against a broad range of cancer cell lines including lung, breast, colon, prostate, brain and overian cancer cell lines. recent study results have shown that jnj-26481585 strongly induce the hdac1-suppressed p21waf1,cip1 promoter in vivo, histone h3 acetylation in tumor tissue and apoptosis in human colon cancer cell lines (both apc wild-type and mutant) in vitro.arts j, king p, mariën a, floren w, beliën a, janssen l, pilatte i, roux b, decrane l, gilissen r, hickson i, vreys v, cox e, bol k, talloen w, goris i, andries l, du jardin m, janicot m, page m, van emelen k, angibaud p. jnj-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. clin cancer res. 2009;15(22):6841-6851
target
HDAC1